Body’s Own Healing Mechanisms Could Reverse Lung Fibrosis
Researchers have identified a molecular pathway that leverages the body's natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
Researchers have identified a molecular pathway that leverages the body's natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
The US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
The study is investigating the possibility that X-ray imaging, when used with artificial intelligence, could facilitate earlier diagnosis and eventually more effective management of idiopathic pulmonary fibrosis.
Read MoreApproximately 11% of hospitalized COVID-19 patients had fibrotic patterning after recovery from acute illness, according to a new study from Imperial College London researchers published in AJRCCM.
Read MoreMUC5AC, an airway protein, plays an important (and overlooked) role in the body’s mucociliary clearance system, according to research published in Science Advances.
Read MoreZinc, a common mineral, may reverse lung damage and improve survival for patients with idiopathic pulmonary fibrosis (IPF), according to researchers from the Women’s Guild Lung Institute at Cedars-Sinai.
Read MoreImportant research results from five studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease (ILD) are being presented at ATS 2022.
Read MoreUpdated clinical practice guidelines from ATS/ERS cover idiopathic pulmonary fibrosis and address progressive pulmonary fibrosis in patients with interstitial lung diseases other than IPF.
Read MoreA study in the journal Respiration showed that patients with idiopathic pulmonary fibrosis who were treated with nintedanib saw more positive outcomes.
Read MoreBoehringer Ingelheim’s BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.
Read MoreRepeated injury to the epithelial tissue of the airways causes “biological aging” of the stem cells located there, which plays a significant role in the development of chronic lung disease.
Read MoreTo drive awareness of interstitial lung disease, nine organizations are collaborating to present the first-ever ILD Day on September 15.
Read MoreBroadway actor Julie Halston recently won a Tony Award in recognition of her pulmonary fibrosis advocacy work.
Read MoreResearch shows it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
Read More